RecruitingNot ApplicableNCT07233928

Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers

Sponsor

Institut Claudius Regaud

Enrollment

1,050 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Breast Cancer Early Breast Cancer

Summary

This trial is a translational, open-label, monocentric and prospective cohort study of participants with breast cancer aiming to create a combined ESPRESSO (= organelle properties) phenotype and spatial proteomics data collection encompassing four cohorts: * TN eBC = cohort A, * HER2+ eBC = cohort B, * Luminal eBC = cohort C, * dnMBC = cohort D. In total 1050 participants will be enrolled in the study. Laboratory analysis (including ESPRESSO technique) will be conducted on the biological specimen collected during this study. The primary objective is to describe the amount of fatty acids accumulated in lipid droplets, within the four cohorts. As a secondary objective, the analysis will expand to other organelles like lysosomal acidity and nuclear organization. The study is due to last 9 years (4 years of recruitment and 5 years of study participation)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is analyzing detailed biological properties of breast cancer cells — including their protein expression and cellular structures — across the three main subtypes of breast cancer: triple-negative, HER2-positive, and hormone receptor-positive (luminal). The goal is to build an atlas that helps researchers better understand and treat each subtype. **You may be eligible if...** - You are 18 or older (any gender) - You have been diagnosed with breast cancer confirmed by biopsy - You have early breast cancer or newly diagnosed metastatic breast cancer - Your tumor falls into one of the three main immunohistochemical subtypes (triple-negative, HER2-positive, luminal A-like, or luminal B-like) **You may NOT be eligible if...** - Your cancer is not one of the three main breast cancer subtypes covered by the study - You have previously treated metastatic breast cancer (not newly diagnosed) - You are unable to provide a tissue sample for analysis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTumor biopsy

As fresh tumor material is required for laboratory analysis purposes (ESPRESSO technique), tumor biopsies will be performed specifically for this study.

Locations(1)

Institut Universitaire du Cancer de Toulouse - Oncopole

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07233928

Related Trials

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081205 locations

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239192 locations

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357108 locations

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT0642839641 locations

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

NCT0545561910 locations